AlzeCure Pharma AB (publ) (STO:ALZCUR)
Sweden · Delayed Price · Currency is SEK | Market Cap | 1.05B +209.2% |
| Revenue (ttm) | 97.33M |
| Net Income | 30.72M |
| EPS | 0.27 |
| Shares Out | 137.90M |
| PE Ratio | 28.16 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 176,273 |
| Open | 7.56 |
| Previous Close | 7.50 |
| Day's Range | 7.46 - 7.74 |
| 52-Week Range | 1.30 - 8.68 |
| Beta | -0.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About AlzeCure Pharma AB
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857 and ACD680 that... [Read more]
Financial Performance
Financial StatementsNews
AlzeCure Pharma AB Transcript: Investor update
Two major out-licensing deals with Eli Lilly and QuantumCell, totaling $3.2 billion, validate the business model and provide strong upfront funding. The pipeline targets Alzheimer's and pain, with clinical progress in both areas and a focus on advancing and out-licensing new assets.
AlzeCure Pharma AB Press release: Investor update
AlzeCure Pharma AB issued a press release on September 18, 2026, disclosing material business information to investors.
AlzeCure Pharma AB Slides: Pareto Securities Capital Market Days presentation
AlzeCure Pharma AB has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2026.
AlzeCure Pharma AB Quarterly report: Q2 2026
AlzeCure Pharma AB has published its Q2 2026 quarterly earnings report on August 26, 2026.
AlzeCure Pharma AB Transcript: Study update
ACD137, a selective oral TrkA negative allosteric modulator, shows potent analgesic and anti-inflammatory effects in preclinical osteoarthritis and neuropathic pain models, with a favorable safety profile and potential disease-modifying benefits. It is advancing toward clinical trials and attracting market interest.
AlzeCure Pharma AB Press release: Study update
AlzeCure Pharma AB issued a press release on May 26, 2026, disclosing material business information to investors.
AlzeCure Pharma AB Slides: Study update
AlzeCure Pharma AB has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
AlzeCure Pharma AB Slides: ABGSC Investor Days
AlzeCure Pharma AB has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
AlzeCure Pharma AB Quarterly report: Q1 2026
AlzeCure Pharma AB has published its Q1 2026 quarterly earnings report on May 5, 2026.
AlzeCure Pharma AB Annual report: Q4 2025
AlzeCure Pharma AB has published its Q4 2025 annual report on February 26, 2026.
AlzeCure Pharma AB Quarterly report: Q4 2025
AlzeCure Pharma AB has published its Q4 2025 quarterly earnings report on February 26, 2026.
AlzeCure Pharma AB Quarterly report: Q3 2025
AlzeCure Pharma AB has published its Q3 2025 quarterly earnings report on November 11, 2025.